Study of the pathogenic potential of Dientamoeba fragilis in experimentally infected mice  by El-Gayar, Eman K. et al.
Parasite Epidemiology and Control 1 (2016) 136–143
Contents lists available at ScienceDirect
Parasite Epidemiology and Control
j ourna l homepage: www.e lsev ie r .com/ locate /parep iStudy of the pathogenic potential of Dientamoeba fragilis in
experimentally infected miceEman K. El-Gayar a,⁎, Amira B. Mokhtar a, Wael A. Hassan b
a Medical Parasitology Department, Faculty of Medicine, Suez Canal University, Egypt
b Pathology Department, Faculty of Medicine, Suez Canal University, Egypt, Ismailia, 41522, Egypta r t i c l e i n f o⁎ Corresponding author at: Ismailia, Suez Canal Unive
E-mail address: ekamal71@yahoo.com (E.K. El-Gaya
http://dx.doi.org/10.1016/j.parepi.2016.05.002
2405-6731/© 2016 Published by Elsevier Ltd on b
(http://creativecommons.org/licenses/by/4.0/).a b s t r a c tArticle history:
Received 21 March 2016
Received in revised form 14 May 2016
Accepted 15 May 2016
Available online 28 May 2016Dientamoebafragilis (D. fragilis) is a protozoan parasite whose pathogenic potential is still dis-
putable. The aim of this study was to illustrate the pathogenicity of D. fragilis infection and
to determine the infective dose for experimental mice infection. Three groups of mice (8/
each) were orally inoculated with in vitro cultured D. fragilis. The infected groups (G1- G3) re-
ceived 103, 105 and 4 × 106 D. fragilis/0.5 ml culture, respectively. A control group (G4) only
received parasite-free culture. Two weeks post-inoculation all mice were euthanized for histo-
pathological examination. All mice of G3 (100%) and three mice of G2 (37.5%) were infected,
and the results were conﬁrmed by PCR and different staining methods. On the other hand,
all mice from group G1 showed a completely negative result. Histopathological examination
of the colon and caecum of the highly infected group G3 showed active colitis, with inﬁltration
of mixed inﬂammatory cells such as eosinophils, neutrophils and lymphocytes within the lam-
ina propria of the intestinal wall. The parasite was not invading the colonic mucosa. This study
revealed that infection with D. fragilis is dose-dependent. Moreover, a dose of 105 D. fragilis/
mouse or higher is necessary to infect mice through the oral route. In addition, this route of
infection, although non-invasive, can induce severe inﬂammatory changes to the colonic and
caecal mucosa in experimentally infected mice.
© 2016 Published by Elsevier Ltd on behalf of World Federation of Parasitologists. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords:
Dientamoeba fragilis
Experimental mice infection
Infective dose1. Introduction
Dientamoeba fragilis was ﬁrst described in 1918 as a binucleated, unﬂagellated protozoan that inhabits the large intestine
(Jepps and Dobell, 1918). On electron microscopy, it has been reclassiﬁed as an amoeba‐ﬂagellate rather than an amoeba
(Camp et al., 1974). It has a worldwide distribution in both urban and rural areas with infection rates ranging from 0.5% to
16%, where higher rates were reported in outbreaks and associated to the lack of personal hygiene (Girginkardeşler et al.,
2008). In adults, asymptomatic colonization is present in 75‐85% of individuals affected by the parasite while in children; disease
develops in as many as 90% of those colonized (Crotti et al., 2005). Similar to some other parasites (e.g., Giardia lamblia, Cyclospora
cayetanensis, Cryptosporidium spp.), the parasite D. fragilis has been showed to cause disease in humans regardless of their immune
status. Abdominal pain/discomfort and diarrhea are the symptoms most often described in patients harboring Dientamoeba. Other
symptoms may include fecal urgency, vomiting, nausea, anorexia, weight loss and fever (Cuffari et al., 1998; Norberg et al., 2003;
Stark et al., 2010). The parasite is increasingly recognized as a relatively common cause of human diarrhea and long-term chronicrsity, Faculty of Medicine, Medical Parasitology Department, Egypt.
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tinal parasites. A study investigated 1497 conﬁrmed D. fragilis cases and found coinfections with Blastocystis spp. in 40.3%, with
Endolimax nana in 24%, and with Entamoeba coli, G. lamblia and Entrobius vermicularis in 6, 5.7 and 5% of the cases, respectively
(Ayadi and Bahri, 1999).
D. fragilis cells tend to infect the mucosal crypts of the large intestine from the caecum to the rectum, which is located close to
the mucosal epithelium (Levine et al., 1980). In addition, this parasite is not known to be invasive and does not cause cellular
damage. It may elicit an eosinophilic inﬂammatory response in the colonic mucosa. Thus, symptoms are related to the irritation
of the superﬁcial colonic mucosal, and it has been reported to be associated with marked peripheral eosinophilia (Gray et al.,
2013).
Despite the evidence supporting its pathogenic nature (Stark et al., 2006), it is apparent that a degree of uncertainty still surrounds
the pathogenic potential of D. fragilis (Ayadi and Bahri, 1999; Banik et al., 2011). To be recognized as a true pathogen Koch's postulate
must be fulﬁlled forDientamoeba as a cause of gastrointestinal illness. Studies conducted to investigate the biology of this parasite are
limited by methods of in vitro cultivation, with difﬁculties in establishment of long-term cultures. It is commonly observed that
D. fragilis grows in vitro for only few subcultures before dying out (Clark and Diamond, 2002; Munasinghe et al., 2012). Moreover,
the lack of an animal model for dientamoebiasis hinders the ability to demonstrate its pathogenicity (Barratt et al., 2011). However,
recently few experimental studies have been carried out (Munasinghe et al., 2013; Eida et al., 2015). This study aimed to investigate
the suitability of mice as an animal model for experimental D. fragilis infection, and to determine the required infective dose. In
addition, we studied the pathological changes caused by D. fragilis infection in experimentally-challenged mice.
2. Subjects and methods
2.1. Isolation of D. fragilis
The study was conducted from September 2015 to February 2016, in the Parasitology Department, Faculty of Medicine, Suez
Canal University, Ismailia. Fecal specimens were collected from patients seeking medical care for different gastrointestinal com-
plaints such as acute or chronic intermittent diarrhea, or diarrhea alternating with constipation, with or without abdominal
pain and attending Outpatient Clinics of Suez Canal University and General Hospitals (Ismailia, Egypt). Fresh stool specimens
were immediately examined microscopically by direct smear and Lugol's iodine for detection of D. fragilis and to exclude other
intestinal parasites followed by formalin ethyl acetate concentration technique (Garcia, 2009). Positive samples for D. fragilis
were further stained with 10% Giemsa stain (Crotti et al., 2005). Modiﬁed acid-fast and trichrome stains were performed to
exclude infection of patients with other parasites e.g. Cryptosporidium, Cyclospora, Cystoisospora and Microsporidium spp. (Garcia,
2009). Culture for common enteric bacterial pathogens was done to exclude them (LiPuma et al., 2007). Culture on Jones'
media without rice starch was done to exclude infection with Blastocystis spp. Positive samples for D. fragilis were cultivated in
the modiﬁed Boeck and Drbohlav (MBD) medium supplemented with antibiotics (Sawangjaroen et al., 1993). The culture was in-
cubated at 37°C for 96h. Each day, the sediment of the culture tubes was examined by light microscopy with ×40 objectives for
trophozoites. Daily count of the number of D. fragilis trophozoites was done using a Neubauer chamber to adjust the inoculation
dose to 103, 105 and 4 × 106 D. fragilis/0.5 ml culture medium.
2.2. Experimental animal infection
Throughout the study, thirty-two 5–6weeks old immune-competent albino Balb/c mice, weighted 25–30 g, were purchased
from the Veterinary Medicine Animal Lab, Suez Canal University. Mice were housed independently in good ventilated, ﬁlter-top
cages and provided sterile rodent chow and water ad libitum. The cage bedding was changed every day to avoid and reduce
the potential for fecal contamination occurring during the experiment. The animals were maintained in animal house at the
faculty of Medicine, Suez Canal University at 25°C, and with a relative humidity of 40–60%.The mice were conﬁrmed to be
parasite-free by screening for several days by light microscopy, modiﬁed acid-fast and trichrome stain fecal smears for protozoa
prior to infection with D. fragilis. Mice were randomly divided into four groups. The ﬁrst three groups were inoculated with
D. fragilis harvested from 4day-old cultures, at different doses: 103, 105, and 4×106 D. fragilis trophozoites/0.5 ml culture medium
given orally to G1, G2 and G3, respectively. The fourth group G4 (uninfected control) was given parasite-free culture media
(0.5 ml/mouse). Oral inoculation was performed via 18G ball-tipped feeding needle attached to 1 ml syringe. All mice were mon-
itored daily for weight loss, presence of loose stool or mucous in stool, lethargy and fur loss from day 1 to day 14 post inoculation.
All mice were euthanized 2weeks post-inoculation. All applicable international, national, and/or institutional guidelines for the
care and use of animals were followed in this study.
2.3. Detection of D. fragilis in feces and intestine
Feces from all mice were examined microscopically by wet mount preparation at the 2nd, 4th and 8th day post-inoculation;
also the intestinal content of sacriﬁced mice was examined. Culture on MBD media was done for negative specimens. In this case,
cultures were considered negative if the organism was absent until the 7th day post-challenge.
To conﬁrm the presence of D. fragilis in infected mice, genomic DNA was extracted from feces of all mice in the infected groups
(G1–G3) using the QiaAMP DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. DNA was
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the following primers; DF400 (5′TATCGGAGGTGGTAATGACC3 ′) and DF1250 (5′CATCTTCCTCCTGCTTAGACG3 ′). The reaction con-
ditions were as follows: pre-denaturation at 94°C for 3 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at
57°C for 1.5min, and extension at 72°C for 2min. DNA extracted from a D. fragilis positive sample was used as a positive control
for PCR. A negative control PCR reaction mixture containing no input DNA was used. The ampliﬁed products were separated by
electrophoresis in 1% agarose gels (Sigma, USA) in Tris–borate–EDTA buffer. Gels were stained with 0.5% ethidium bromide and
photographed using an ultraviolet gel documentation system (UVP Biospectrum, UK) for the presence of speciﬁc bands at
870bp (Stark et al., 2005).
2.4. Histopathological examination
Two weeks post infection mice were anesthetized and euthanized. Large intestine (colon and caecum) was assessed by naked
eye, removed, preserved in 10% formalin, cut into three to ﬁve equal cross-sections and processed in parafﬁn blocks. Intestinal
sections (4–8μm thickness) were stained with hematoxylin and eosin (H&E) for histopathological examination. Three sections
were made from each tissue specimen (each separated by at least 500μm). Histopathological changes were scored blindly for
eachmouse. Degree of inﬂammationwas scored from0 to 4 (0, normal; 1,mucosal hyperplasia; 2, spotty inﬁltration by inﬂammatory
cells not involving the entire thickness of the mucosa; 3, marked increase of inﬂammatory cells involving full thickness of mucosa;
4, marked increase of inﬂammatory cells in mucosa and submucosa, with tissue intact architecture (Hamano et al., 2006).
3. Results
3.1. Infectivity of D. fragilis
The results obtained from mice inoculated orally with D. fragilis are summarized in Table 1. During the period of the experi-
ment, no infection occurred in the ﬁrst group (G1), three mice became infected in G2 and the infection appeared on the fourth
day post-inoculation, while all mice in G3 became infected 2 days post-inoculation. All mice in G3 showed loss of weight 2.5–
3 g (about10% of the original body weight), decreased activity and diarrheic loose stool. While the three infected mice in G2
showed semi-formed stool without loss of weight.
3.2. Detection of D. fragilis in stools and intestinal contents
By direct examination of stool samples both trophozoite and presumptive cyst stages were detected in infected mice
(Fig. 1).The average number of D. fragilis (trophozoite & presumptive cyst forms)/high power ﬁeld (HPF) in the stool of the infect-
ed mice in each of the infected groups is shown in Fig. 2. Culture in MBD media was performed for positive stool samples to
conﬁrm the presence of the parasite. The stool samples and intestinal contents of all mice in G1 and the ﬁve mice in G2 which
were microscopically negative were cultivated in MBD media and examined for 7days but no growth was detected. All infected
mice with D. fragilis were conﬁrmed by PCR through detection of the 870bp band targeting the SSUrRNA (Fig. 3).
3.3. Histolopathological examination
Naked eye examination of large intestine showed bloated, congested large intestine with loose diarrheic stool. Histopathological
examination of G3 showed marked inﬂammatory inﬁltrates of mucosa and submucosa in colonic wall. In addition, the inﬂammatory
inﬁltrates were composedmainly of eosinophils, lymphocytes andmacrophages. Therewas also hyperplasia in colonic glands, edema
in colonic submucosa, congested blood vessels in submucosa and hypertrophied muscle layer was evident. The degree of inﬂamma-
tion ranged between 4 and 5 degrees of inﬂammation. On the other hand, the histopathological examination of the three infected
mice in G2 showed spotty inﬂammatory areas and mucosal hyperplasia and was scored as 1 to 2 degree of inﬂammation. D. fragilis
did not inﬁltrate the colonic or caecal wall (Fig. 4).
4. Discussion
Dientamoeba fragilisis a cosmopolitan occurring protozoan parasite found in human's mucosal crypts of the large intestine from
caecum to rectum (Windsor et al., 2006). There is a debate about its pathogenic role, since it was considered a harmlessTable 1
infectivity of D. fragilis to study groups through oral experimental infection.
Studied group Inoculuma N of mice/+ (%)
G1 103 8/0 (0)
G2 105 8/3 (37.5)
G3 4 × 106 8/8 (100)
a Number of D. fragilis in 0.5 ml culture media.
Fig. 1. D. fragilis trophozoite irregular and rounded forms inwetmount (a– c), irregular form showing inclusions of rice (d), Giemsa-stained trophozoites binucleated (e) and
uninucleated (f), trichrome-stained trophozoite (g, h) and precyst (i), presumptive cyst bywetmount ( j) and iodine-stained (k), rounded form trophozoite inMBD culture.
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Such symptoms tend to improve in most cases with the elimination of the parasite by anti-parasitic treatment (Stark et al., 2010).
Other studies reported that infection with D. fragilis could have a self-limiting character because patients improved without treat-
ment (Stumpel et al., 2006; Vandenberg et al., 2006).Fig. 2. Dientamoeba fragilis intensity in direct stool smears of infected mice at different intervals post-inoculation. Data are expressed as average N/HPF.
Fig. 3. PCR products of D. fragilis isolated from stool samples of infected mice on 1% agarose gel stained with ethidium bromide. Lane M, molecular weight marker
(100bp); lane 1, positive control; lane 2, negative control; lanes 3–5, infected animal samples with positive ampliﬁcation of D. fragilis SSU rRNA at 870bp. 6 and 7
correspond to negative animal samples.
Fig. 4. H&E sections of the large intestine of groups G3 (ﬁgures a, b, c, d and e) and G2 (ﬁgure f). a, b: marked inﬂammatory inﬁltrate of mucosa and submucosa in
colonic wall (black arrow), with surface erosion (red arrow) (20× and 10×, respectively), c: higher magniﬁcation of the inﬂammatory inﬁltrate showing eosino-
phils, lymphocytes and macrophages (40×), d: areas of colonic mucosa showing chronic inﬂammatory cell inﬁltrate (arrow head) within edematous stroma (red
arrow) and congested blood vessels in submucosa (blue arrows) (10×), e: hyperplastic muscle layer (arrow head) is evident (10×), f: spotty inﬁltration by chronic
inﬂammatory cells (black arrow) with hyperplastic colonic glands (20×).
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role. It has been reported that D. fragilis causes colitis by an invasive ulcerative process. This conclusion was based on the discov-
ery of numerous ulcers in the intestine of a female patient infected with D. fragilis (Shein and Gelb, 1983). Furthermore, ﬂat
ulcerations together with acute and chronic inﬂammation, could be demonstrated in a biopsy taken from this patient. Another
study showed that there were inﬂammatory changes in the mucosa of the rectum and sigmoid colon in D. fragilis-infected pa-
tients. In particular, superﬁcial rounded inﬁltrations of cells in loosened stroma were observed, giving a picture of low-grade
chronic proctitis (Ockert and Schulz, 1972). On the other hand, it was shown that multiplication of D. fragilis in the presence
of suitable bacterial intestinal ﬂora could cause disturbance of intestinal functions. It has been suggested that, the association of
bacteria with D. fragilis, can develop ampliﬁed intestinal secretions, that may lead to the development of a suitable environment
for the colonization by, and multiplication of D. fragilis (Lamy, 1960).The present study was performed to study the infectivity and
pathogenicity of D. fragilis and to determine the proper number of the parasite for experimental mice infection.
In this study, all mice orally inoculated with a high dose of 4 × 106 of D. fragilis became infected. The infected mice showed
loss of weight and diarrhea. This is in agreement with a previous study showing that mice infected with D. fragilis experienced an
average weight loss of 2.38g (12%) compared with the control group (Munasinghe et al., 2013).The presence or absence of symp-
toms associated with D. fragilis infection could be due to the presence of different genotypes of D. fragilis. This will be similar to
what it has been described in other enteric protozoa, such as G. lamblia (Barratt et al., 2011). An analysis of D. fragilis ribosomal
genes proved the existence of two genetically distinct pathogenic and nonpathogenic variants (Johnson and Clark, 2000). Never-
theless, only one D. fragilis genotype has been described in symptomatic and asymptomatic patients by several studies
(Vandenberg et al., 2006; Johnson et al., 2004; Rayan et al., 2010). Difference in parasitic load in the colon can also play a role,
observing a dose depending onset of symptoms. When the number of protozoa exceeds this threshold, their pathogenic effect
can be observed. So, in the presence of appropriate intestinal bacterial ﬂora, a gradual physiologic change of the protozoan cell
could cause a qualitative alteration of the parasite's enzyme activity. Theoretically, a higher parasitic DNA load would be expected
in patients with more clinical symptoms compared to asymptomatic (de Jong et al., 2014).
For a long time, it was thought that D. fragilis had no cyst stage and the parasite had only a trophozoite stage (Girginkardeşler
et al., 2008; Ockert and Schmidt, 1975; Ghazanchaei et al., 2014). In this study, examination of stool from infected mice showed
trophozoite in its rounded form, which transformed into irregular forms after minutes in the MBD culture media. In addition, it
was observed that the ingested rice starch was present in its cytoplasm. Moreover, a presumptive cyst stage with its characteristic
appearance was present in infected mice feces. The cyst presented a distinct thick cyst wall, with a membranous, irregular inner
cyst wall located directly adjacent to the encysted parasite, surrounded by a distinctive peritrophic space. These observations were
in agreement with previous ﬁndings of cysts in animal models (Munasinghe et al., 2013), as well as in human clinical samples
(Stark et al., 2014).
Eida et al. reported that experimental infection of mice with D. fragilis resulted in histopathological changes in the caecum in
the form of severe crypt hyperplasia, congestion, and edema of the lamina propria of caecal mucosa, and the interglandular epi-
thelial cells were sloughed into the lumen. Moreover, there was penetration of multiple D. fragilis trophozoites in caecal glands
(Eida et al., 2015). In the present study, the histopathological examination of the colon and caecum of mice in G2 showed spotty
inﬂammation with hyperplasia in colonic glands while in heavily infected group G3 there was marked inﬂammatory inﬁltrate of
mucosa and submucosa. The difference in the degree of inﬂammation between the two groups could be attributed to the inocu-
lum doses used in the experiment, which means that D. fragilis infection is dose dependent and its pathogenic effect depends on
the burden of the parasite on the large intestine, as suggested by de Jong et al. (2014). In this study, no D. fragilis trophozoites
were detected invading the colonic mucosa as previously observed in several studies describing lesions of the large intestine in
the form of colitis (Shein and Gelb, 1983), chronic or hemorrhagic proctitis (Ockert and Schulz, 1972) and appendicitis
(Burrows et al., 1954; Swerdlow and Burrows, 1955), but no parasites were detected invading the underlying tissue. These path-
ogenic changes may be due to calprotectin release, which is a neutrophil protein, and its presence in the stool. This observation is
indicative of neutrophilic inﬁltration into the gut lumen associated with inﬂammatory processes. Signiﬁcantly elevated concentra-
tions of fecal calprotectin have been demonstrated in the feces of infected mice experimentally infected with D. fragilis compared
with the controls (Munasinghe et al., 2013). Elevated fecal calprotectin has been reported in patients suffering from intestinal dis-
orders such as inﬂammatory bowel disease (IBD) and inﬂammatory bowel syndrome (IBS) (Costa et al., 2003). Dientamoeba has
also been incriminated as a possible cause of IBS (Stark et al., 2010). Some parasitic infections such as giardiasis (Hanevik et al.,
2007) and intestinal schistosomiasis (Bustinduy et al., 2013) showed similar elevated levels of calprotectin. Calprotectin is thought
to induce inﬂammation through induction of pro-inﬂammatory chemokines, adhesion molecules and β2-integrin, thereby mediat-
ing leukocyte recruitment, adhesion, and trans-endothelial migration to inﬂamed tissue (Viemann et al., 2007; Foell et al., 2009).
Moreover, the neutrophil migration and protein secretion causes epithelial damage or cell death (apoptosis), which leads to in-
creased intestinal permeability and increased secretion of chloride ion, thus causing diarrhea in symptomatic patients (Lam
et al., 2014).
In conclusion, this study revealed that large numbers of D. fragilis are needed for oral infection of mice. Despite its non-invasive
nature, it can induce severe inﬂammation in the large intestinal mucosa if given in large doses. On the other hand, mice are
considered a suitable animal model for D. fragilis experimental infection and this favors the study of the detailed biology and path-
ogenic mechanisms of this parasite. This is of great relevance to the advancement in the understanding of the pathology of this
emerging parasite. This study suggests the presence of a cyst stage in the life cycle of D. fragilis. Further studies are recommended
to evaluate the cyst infectivity to different lab animals and to study the ultrastructure of cysts, as well as the sequential changes of
encystation through scanning and transmission EM.
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